FDA Hosts Meeting on How Drug Fees Are Really Spent
Published Date: 8/21/2025
Notice
Summary
The FDA is hosting a public meeting to talk about how money from drug user fees is spent and how to make the process clearer and more efficient. This affects drug companies that pay fees for prescription, biosimilar, and generic drugs. They want your ideas soon to help improve transparency and keep things running smoothly without surprises on costs or timing.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA meeting on drug user fees
If you run or work for a company that pays Prescription Drug User Fee Act (PDUFA), Biosimilar User Fee Act (BsUFA), or Generic Drug User Fee Amendments (GDUFA) fees, the FDA is holding a public meeting to discuss how those fee dollars are spent and how to make the process clearer and more efficient. The FDA is asking for public input and ideas to help improve financial transparency and to avoid surprises on costs or timing.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in